Univercells launches new cell and gene focused CDMO Exothera
Exothera's Jumet site
A new contract development and manufacturing organisation to support cell and gene developers with process development and production of viral vectors has been launched by bioprocessing provider Univercells.
In a statement, Univercells said the company, Exothera, has been created to help alleviate a current lack of capacity and scarcity of bioprocessing expertise in the cell and gene manufacturing sector.
“This new focus will enable our team to leverage expertise with innovation to overcome the industry’s production constraints and foster the success of cell and gene therapies” said Hugues Bultot, CEO of Univercells and Exothera.
Following initial activities in established facilities in Gosselies and Nivelles in Belgium, Exothera’s capabilities will be housed at Univercells’ recently bought 15,000 m2 site in Jumet, also in Belgium.
The Jumet site will be revamped to house labs, cleanrooms and GMP manufacturing areas for clinical and commercial production.
The flexible GMP areas at Jumet will contain Exothera’s CDMO activities and ongoing Univercells vaccine development and manufacturing initiatives, with capacity for rapid response programs.
Exothera is currently pursuing support opportunities for COVID-19 vaccine innovators.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance